Boothbay Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Boothbay Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Buy	90,928 +2,549	+3%	+$84.9K	0.04%	521
2026 Q1	$2.66M	Sell	88,379 -25,434	-22%	-$818K	0.03%	513
2025 Q4	$3.55M	Sell	113,813 -85,841	-43%	-$2.11M	0.05%	403
2025 Q3	$4.03M	Buy	199,654 +17,486	+10%	+$307K	0.06%	367
2025 Q2	$3.05M	Buy	+182,168	New	+$2.94M	0.06%	407
2022 Q3	–	Sell	-201,811	Closed	-$1.52M	–	2597
2022 Q2	$1.52M	Buy	201,811 +110,263	+120%	+$961K	0.04%	658
2022 Q1	$860K	Buy	91,548 +12,636	+16%	+$105K	0.02%	992
2021 Q4	$632K	Buy	+78,912	New	+$712K	0.01%	927
2020 Q2	–	Sell	-28,700	Closed	-$258K	–	1109
2020 Q1	$258K	Buy	+28,700	New	+$294K	0.02%	609
2019 Q4	–	Sell	-62,430	Closed	-$430K	–	996
2019 Q3	$430K	Buy	+62,430	New	+$478K	0.04%	500
2015 Q4	–	Sell	-5,899	Closed	-$333K	–	652
2015 Q3	$333K	Sell	5,899 -2,715	-32%	-$176K	0.16%	159
2015 Q2	$509K	Buy	8,614 +4,624	+116%	+$285K	0.2%	91
2015 Q1	$249K	Buy	+3,990	New	+$232K	0.16%	186

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Boothbay Fund Management's TEVA Position: Q2 2026 in Review

Boothbay Fund Management increased its Teva Pharmaceuticals (TEVA) stake by 2.9% in Q2 2026, buying an estimated $84.9K and bringing the position to 90,928 shares worth $3.08M. The position accounts for 0.04% of the portfolio, ranked #521.

Boothbay Fund Management first reported a position in TEVA in Q1 2015 and has held it in 13 quarters since. The position peaked at $4.03M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Boothbay Fund Management held 90,928 shares of Teva Pharmaceuticals worth $3.08M as of Q2 2026.
Boothbay Fund Management bought 2,549 Teva Pharmaceuticals shares in Q2 2026, an estimated $84.9K.
Teva Pharmaceuticals made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #521 holding.
Boothbay Fund Management first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 13 quarters since.
Boothbay Fund Management's Teva Pharmaceuticals position peaked at $4.03M in Q3 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.